Top

Published in:

01-06-2018 | Preclinical study

A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer

Authors: M. Rudolph, S. T. Sizemore, Y. Lu, K. Y. Teng, M. M. Basree, R. Reinbolt, C. D. Timmers, G. Leone, M. C. Ostrowski, S. Majumder, B. Ramaswamy

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Abstract

Purpose

High expression of glioma-associated oncogene homolog-1 (GLI1) is associated with poor prognosis in estrogen receptor (ER) positive breast cancers. We sought to define a GLI1-dependent gene signature in ER-positive tumors that could further stratify patients at higher risk for disease recurrence and potentially lead to novel combination therapies.

Methods

We identified an inverse correlation between GLI1 expression and distant disease-free survival (DFS) using a dataset developed at MD Anderson Cancer Center (Hatzis dataset) containing clinical data from 508 breast cancer patients. Using a qPCR-based microarray platform, we identified genes differentially regulated by GLI1 in MCF7 cells and then determined if expression of these genes correlated with GLI1 expression in patient tumor samples. Statistical comparison between the groups was performed by ANOVA. Direct comparison of two groups was done by a two-tailed t test. Correlations between variables were done by Pearson’s method.

Results

Expression of GLI1 and its target genes correlated significantly with worse distant DFS in breast cancer patients with Luminal A molecular subtype. Particularly, co-expression of GLI1 with EGFR and/or SNAI1, two of the identified GLI1 targets, was predictive of worse distant DFS in this subtype. Furthermore, patients with Luminal A tumors with a high GLI1 signature had a shorter distant DFS compared to the Luminal B subtype and the outcome for this group was comparable to patients with HER2-positive or basal-like tumors.

Conclusion

We have identified a novel GLI1 gene signature that is associated with worse clinical outcomes among the patients with Luminal A subtype of breast cancer.

Available only for authorised users

Ciriello G, Sinha R, Hoadley KA, Jacobsen AS, Reva B, Perou CM, Sander C, Schultz N (2013) The molecular diversity of Luminal A breast tumors. Breast Cancer Res Treat 141:409–420. https://doi.org/10.1007/s10549-013-2699-3 CrossRefPubMedPubMedCentral

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691. https://doi.org/10.1200/JCO.2009.24.9284 CrossRefPubMed

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346–352. https://doi.org/10.1038/nature10983 CrossRefPubMedPubMedCentral

Russnes HG, Navin N, Hicks J, Borresen-Dale AL (2011) Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 121:3810–3818. https://doi.org/10.1172/JCI57088 CrossRefPubMedPubMedCentral

Cm P, Børresen-Dale AL (2011) Systems biology and genomics of breast cancer. Cold Spring Harbor Perspect Biol 3:1–17

Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF (2012) Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomark Prev 21:1848–1855. https://doi.org/10.1158/1055-9965.EPI-12-0474 CrossRef

Ramaswamy B, Lu Y, Teng KY, Nuovo G, Li X, Shapiro CL, Majumder S (2012) Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res 72:5048–5059. https://doi.org/10.1158/0008-5472.CAN-12-1248 CrossRefPubMed

Varjosalo M, Taipale J (2008) Hedgehog: functions and mechanisms. Genes Dev 22:2454–2472. https://doi.org/10.1101/gad.1693608 CrossRefPubMed

Briscoe J, Therond PP (2013) The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol 14:416–429. https://doi.org/10.1038/nrm3598 CrossRefPubMed

10.

Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH, Nephew KP (2006) Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66:11954–11966. https://doi.org/10.1158/0008-5472.CAN-06-1666 CrossRefPubMed

11.

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682. https://doi.org/10.1038/nmeth.2019 CrossRefPubMed

12.

Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305:1873–1881. https://doi.org/10.1001/jama.2011.593 CrossRefPubMedPubMedCentral

13.

Kao KJ, Chang KM, Hsu HC, Huang AT (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11:143. https://doi.org/10.1186/1471-2407-11-143 CrossRefPubMedPubMedCentral

14.

Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, Vega F (2011) ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30:4874–4886. https://doi.org/10.1038/onc.2011.195 CrossRefPubMedPubMedCentral

15.

Cao X, Geradts J, Dewhirst MW, Lo HW (2012) Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells. Oncogene 31:104–115. https://doi.org/10.1038/onc.2011.219 CrossRefPubMed

16.

Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA (2002) Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297:1559–1561. https://doi.org/10.1126/science.1073733 CrossRefPubMed

17.

Hyder SM, Liang Y, Wu J (2009) Estrogen regulation of thrombospondin-1 in human breast cancer cells. Int J Cancer 125:1045–1053. https://doi.org/10.1002/ijc.24373 CrossRefPubMedPubMedCentral

18.

Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D (1999) Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13:787–796. https://doi.org/10.1210/mend.13.5.0274 CrossRefPubMed

19.

Manning DL, Daly RJ, Lord PG, Kelly KF, Green CD (1988) Effects of oestrogen on the expression of a 4.4 kb mRNA in the ZR-75-1 human breast cancer cell line. Mol Cell Endocrinol 59:205–212CrossRefPubMed

20.

May FE, Westley BR (2015) TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer. Endocr Relat Cancer 22:465–479. https://doi.org/10.1530/ERC-15-0129 CrossRefPubMedPubMedCentral

21.

Sengupta S, Sharma CG, Jordan VC (2010) Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Horm Mol Biol Clin Investig 2:235–243. https://doi.org/10.1515/HMBCI.2010.025 PubMedPubMedCentralCrossRef

22.

Wei X, Xu H, Kufe D (2006) MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 21:295–305. https://doi.org/10.1016/j.molcel.2005.11.030 CrossRefPubMed

23.

Li X, Deng W, Nail CD, Bailey SK, Kraus MH, Ruppert JM, Lobo-Ruppert SM (2006) Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation. Oncogene 25:609–621. https://doi.org/10.1038/sj.onc.1209077 CrossRefPubMedPubMedCentral

24.

Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM (2004) HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10:5670–5676. https://doi.org/10.1158/1078-0432.CCR-04-0110 CrossRefPubMed

25.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68:826–833. https://doi.org/10.1158/0008-5472.CAN-07-2707 CrossRefPubMed

26.

Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW (1993) Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 29A:1018–1023CrossRefPubMed

27.

Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200:290–297. https://doi.org/10.1002/path.1370 CrossRefPubMed

28.

Jiang Y, Zhao X, Xiao Q, Liu Q, Ding K, Yu F, Zhang R, Zhu T, Ge G (2014) Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR-ERK independent of epithelial-mesenchymal transition. J Mol Cell Biol 6:352–354. https://doi.org/10.1093/jmcb/mju019 CrossRefPubMed

29.

Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M (2014) uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res 16:428. https://doi.org/10.1186/s13058-014-0428-4 CrossRefPubMedPubMedCentral

30.

Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O’Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94:116–128CrossRefPubMed

31.

Balleine RL, Earl MJ, Greenberg ML, Clarke CL (1999) Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer 79:1564–1571. https://doi.org/10.1038/sj.bjc.6690249 CrossRefPubMedPubMedCentral

32.

Fagan DH, Uselman RR, Sachdev D, Yee D (2012) Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 72:3372–3380. https://doi.org/10.1158/0008-5472.CAN-12-0684 CrossRefPubMedPubMedCentral

33.

Horwitz KB, Koseki Y, McGuire WL (1978) Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103:1742–1751. https://doi.org/10.1210/endo-103-5-1742 CrossRefPubMed

34.

Kasper G, Weiser AA, Rump A, Sparbier K, Dahl E, Hartmann A, Wild P, Schwidetzky U, Castanos-Velez E, Lehmann K (2005) Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients. Int J Cancer 117:961–973. https://doi.org/10.1002/ijc.21235 CrossRefPubMed

35.

Carlson RW, O’Neill A, Vidaurre T, Gomez HL, Badve SS, Sledge GW (2012) A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 133:1049–1056. https://doi.org/10.1007/s10549-012-1997-5 CrossRefPubMedPubMedCentral

36.

Das S, Samant RS, Shevde LA (2013) Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting Hedgehog inhibition. J Biol Chem 288:11824–11833. https://doi.org/10.1074/jbc.M112.432302 CrossRefPubMedPubMedCentral

37.

Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ (2009) Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326:572–574. https://doi.org/10.1126/science.1179386 CrossRefPubMedPubMedCentral

38.

Ribelles N, Perez-Villa L, Jerez JM, Pajares B, Vicioso L, Jimenez B, de Luque V, Franco L, Gallego E, Marquez A, Alvarez M, Sanchez-Munoz A, Perez-Rivas L, Alba E (2013) Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res 15:R98. https://doi.org/10.1186/bcr3559 CrossRefPubMedPubMedCentral

Title: A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer
Authors: M. Rudolph
S. T. Sizemore
Y. Lu
K. Y. Teng
M. M. Basree
R. Reinbolt
C. D. Timmers
G. Leone
M. C. Ostrowski
S. Majumder
B. Ramaswamy
Publication date: 01-06-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4718-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine

Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Breast cancer subtype and survival by parity and time since last birth

Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer